# Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy

> **NCT00970905** · PHASE2 · COMPLETED · sponsor: **University of Vermont** · enrollment: 52 (actual)

## Conditions studied

- Nausea
- Vomiting

## Interventions

- **DRUG:** aprepitant
- **DRUG:** Ondansetron

## Key facts

- **NCT ID:** NCT00970905
- **Lead sponsor:** University of Vermont
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2016-07-01
- **Final completion:** 2016-08-01
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2017-12-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00970905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00970905, "Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00970905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*